Furthermore, KN026, a BSAB targeting the same epitope as zanidatamab, demonstrated encouraging antitumor activity in 63 patients with metastatic BC who failed HER2-targeted therapy (KN026 dose: 20 mg/kg, q2w and 30 mg/kg, q3w), with a DCR of 76.8% and an ORR of 32.1% [169]. Here, ERBB2 is linked to breast cancer.